Aprea

About:

Aprea is a biopharmaceutical company that develops novel cancer therapeutics.

Top Investors: National Cancer Institute, Keiretsu Capital, Janus Henderson Investors, Dafna Capital Management, Redmile Group

Description:

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

Total Funding Amount:

$136M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Stockholm, Stockholms Lan, Sweden

Founded Date:

2003-01-01

Contact Email:

info(AT)aprea.com

Founders:

Galina Selivanova, Klas Wiman

Number of Employees:

1-10

Last Funding Date:

2024-03-11

IPO Status:

Public

Industries: